News
High eradication, fewer adverse events with hybrid therapy for H. pylori
High-dose dual therapy had the lowest frequency of adverse events, but significantly lower eradication rates versus hybrid or quadruple therapies...
News
Liver transplant outcomes improving for U.S. patients with HIV/HCV
Hepatitis C virus infection no longer confers worse patient survival in the era of DAA therapy, but the population remains underserved.
News
Racial and ethnic minorities underrepresented in pancreatic cancer clinical trials
Better inclusion of underrepresented minorities in clinical trials is critical to reducing health care disparities and improving patient outcomes...
News
Severe IBS symptoms may have improved during COVID-19 lockdowns
IBS symptoms were expected to worsen, fueled by new stresses and pressures related to the nationwide lockdown, but now that hypothesis has changed...
News
Severe IBS symptoms may improve during COVID-19 lockdowns
IBS symptoms were expected to worsen, fueled by new stresses and pressures related to the nationwide lockdown, but now that hypothesis has changed...
News
Liver, gastric cancer disparities consistent across race and ethnicity
These data clearly highlight the need to step up efforts to help level gastrointestinal cancer disparities, commented Dr. Byron Cryer.
News
High teen BMI linked to stroke risk in young adulthood
Finding holds true for men and women, even for those individuals with BMIs in the high-normal range.
News
Exercise plus liraglutide better for maintaining weight loss than either strategy alone
Study findings also support the feasibility of moderate to vigorous exercise interventions even in individuals with obesity who had a very low...
News
ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma
News
Allogeneic transplant leads to durable remissions in T-cell lymphomas
Retrospective study demonstrates overall survival over 50% at 5 years, though transplant-related mortality and graft-versus-host disease need to...
News
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
Article
ASCO advises against PARP inhibitor retreatment in ovarian cancer
ASCO guidelines detail recommendations for PARP inhibitor treatment in ovarian cancer.